血管内皮细胞生长因子检测在重型肝炎患者中的应用

目的：探讨检测血管内皮细胞生长因子（VEGF）水平在重型肝炎患者中的临床应用，为其预后提供早期诊断依据。方法：采用双抗体夹心法定量检测80例重型肝炎患者血清VEGF水平。结果：急、慢性重型肝炎患者VEGF检出率分别为39．09％和81．36％。慢性期恢复率升高差异有显著性意义（P〈0．01），存活组和死亡组检出率分别高于正常组，存活组恢复期检出率达81．96％（P〈0．01），而死亡组恢复期检出率明显下降达21．05％（P〈0．05）。血清VEGF检测灵敏度为15pg／ml，特异性强，重复性好，板内板间变异系数均〈9．5％。结论：血清VEGF水平检测具有较好的特异性和敏感性，可反映重型肝炎患者肝细胞再生程度，是临床观察重型肝炎患者预后具有特征性的疗效指标。     

重型肝炎患者血清胰岛素样生长因子-1含量及其临床意义

目的:研究重型肝炎患者血清胰岛素样生长因子(IGF-1)含量的动态变化及其对评估重型肝炎预后的意义.方法:采用ELISA定量检测47例重型肝炎患者及18例健康体检者血清IGF-1含量,同时检测有关肝功能指标.结果:死亡组治疗前IGF-1含量显著低于正常对照[(186.37±71.46)ng/ml vs (247.06±48.81)ng/ml,P＜0.01],其死亡前含量显著低于入院时含量[(131.70±43.79)ng/ml vs (186.37±71.46)ng/ml,P＜0.01].存活组治疗前IGF-1含量和正常对照组差异无显著性意义[(209.44±71.96)ng/ml vs (247.06±48.81)ng/ml,P＞0.05],其治疗后含量显著高于死亡组死亡前含量[(198.55±56.68)ng/ml vs (131.70±43.79)ng/ml,P＜0.01].IGF-1含量和部分肝功能指标(PTA、CHO、CHE)相关(P＜0.05).结论:IGF-1可以反映肝细胞增生情况,动态检测能较好预测重型肝炎发展趋势,对评估重型肝炎预后有一定价值.     

原发性肺癌患者血清血管内皮细胞生长因子检测的临床意义

新近发现 ,肿瘤血管形成与肿瘤浸润转移及预后密切相关 ,肿瘤血管形成受血管生成抑制因子和血管形成促进因子的共同调节 ,其中血管内皮细胞生长因子 ( CVEGF)是最有效和特异的生长因子。2 0 0 0年 3月至 2 0 0 2年 2月 ,我们对原发性支气管肺癌患者进行了血清 VEGF含量检测 ,以探讨血清VEGF含量与肺癌的关系。现报告如下。1　资料与方法1 .1　临床资料　选取山东省肿瘤医院 87例手术患者 ,男 65例 ,女 1 4例 ;年龄 32～ 76岁 ,平均 ( 5 7±1 7)岁。有吸烟史 40例 ,嗜酒 31例 ;原发性肺癌 79例 ,肺良性实质性病变 8例 ( 4例炎性假瘤 ,2…     

急性白血病患者血清血管内皮细胞生长因子测定及临床意义

目的探讨血管内皮细胞生长因子(VEGF)在急性白血病(AL)患者中的表达和临床意义.方法采用双抗体夹心ELISA法检测了41例AL初发患者(ANLL32例,其中是M14例、M24例、M38例、M44例、M512例和ALL9例)血清VEGF含量,并且检测了其中10例获得完全缓解后的AL患者血清VEGF水平;同时留取41例AL初发患者和10例获得完全缓解后AL患者骨髓涂片,进行瑞特染色后检测骨髓原始和幼稚细胞百分率.结果血清VEGF在ANLL和ALL中分别是(807.76±347.04)ng/L、(998.18±387.80)ng/L,均高于正常对照组(461.43±127.05)ng/L,均P＜0.01;ANLL和ALL之间血清VEGF水平差异无统计学意义(P＞0.05);10例完全缓解的AL患者,其血清VEGF含量为(495.28±102.79)ng/L明显低于初发时(1263.44±490.39)ng/L,P＜0.01;AL缓解组血清VEGF含量与其骨髓中原始幼稚白细胞百分率具有一定相关性,r=0.57,P＜0.01.结论血清VEGF在AL患者中明显升高,且血清VEGF水平与病情和预后密切相关.     

急性脑梗死患者血清与脑脊液中血管内皮细胞生长因子含量的变化

血管内皮细胞生长因子(vascular endothelial growth factor,VEGF)是一种特异性作用于血管内皮细胞、具有分裂原作用、促进血管生成和增强血管通透性作用的细胞因子。对血管闭塞性疾病具有促进侧支循环建立的作用。我们观察脑梗死患者血清与脑脊液(CSF)中VEGF含量的变化,探讨VEGF与脑梗死的关系。     

肺结核患者血管内皮细胞生长因子的测定及临床意义

血管内皮细胞生长因子(valscular endothelial growth factor，VEGF)是一种特异性促使内皮细胞激活、增殖及直接参与血管增生的糖蛋白，资料显示血清VEGF与肺结核、结核性脑膜炎的发生、发展亦有关。我们测定了肺结核病人治疗前与治疗过程中的血清VEGF，并与肺癌患者比较。结果报告如下。     

肝细胞生长因子与重型肝炎

肝细胞生长因子（ＨＧＦ）最初从重型肝炎患者血清中分离提纯，在体外有促进原代肝细胞ＤＮＡ合成作用。以后分别从部分肝切除的患者或大鼠血清中分离，从大鼠血小板中检出，最后证实为同一物质。由于其具有促进肝细胞再生作用而与重型肝炎关系密切，本文就ＨＧＦ与重型肝炎关系的研究现况作一介绍。一、重型肝炎时ＨＧＦ的检出ＨＧＦ前身为单链的ＨＧＦ原，肝损伤时其为丝氨酸蛋白酶激活，产生ＨＧＦ。在重型肝炎肝组织广泛损伤时，这一转换作用增强。急性肝炎患者血清ＨＧＦ水平可上升２～３倍，在肝癌和肝硬化时可有轻度升高。慢性肝功能…     

恶性淋巴细胞增殖性疾病患者血清血管内皮细胞生长因子水平检测

血管内皮细胞生长因子(VEGF)是血管生成的重要调节因子之一，多种造血系肿瘤细胞表达并分泌VEGF，它不仅在肿瘤血管生成中起重要作用，还可能以自分泌或旁分泌机制刺激肿瘤细胞生长。本实验通过双抗体夹心酶联免疫吸附法(ELISA)方法检测了60例恶性淋巴细胞增殖性疾病患者血清VEGF水平，并通过与健康组的对照研究探讨VEGF在恶性淋巴细胞增殖性疾病中的临床意义。     

白血病患者免疫表型与血管内皮细胞生长因子受体的关系

目的:探讨血管内皮细胞生长因子受体(VEGFR)与白血病患者免疫表型的关系及作用机制。方法:对39例初发或复发的白血病患者和6例无血液系统及其他系统恶性肿瘤患者,采用流式细胞仪测定免疫表型及VEGFR阳性表达。结果:39例白血病患者中32例VEGFR阳性表达,其表型阳性占82．1％。各组单个核细胞VEGFR表达阳性率分别为:髓系白血病组(56．03±20．00)％;淋系白血病组(90．61±11．81)％;髓系抗原表达的淋系白血病组(91．66±1．63)％;淋系抗原表达的髓系白血病组(66．99±33．94)％;杂合型白血病组66．47％;6例对照组(17．46±3．96)％。VEGFR阳性表达率>90％高表达的14例白血病患者中有9例均单纯表达淋系抗原,表达髓系的有4例。结论:血管内皮细胞生长因子(VEGF)及其受体可能通过自分泌和(或)旁分泌机制参与白血病的发生发展。因此,对VEGFR高表达患者选用干扰VEGF和VEGFR信号途径的药物治疗,可能提高缓解率,延长患者生存期。     

IgA肾病患者血管内皮细胞生长因子及其受体的表达

肾小球内皮细胞是肾小球血管壁的重要组成部分 ,对于维护肾小球血管壁的完整性具有重要的意义。血管内皮细胞生长因子 (VEGF)能促进内皮细胞的增生、迁移 ,增强内皮细胞通透性。本研究通过观察IgA肾病患者肾组织内VEGF及其受体 (flk 1 )和Ⅳ型胶原的表达 ,分析VEGF、flk 1表达与IgA肾病患者尿蛋白、血压、血肌酐、肾小球Ⅳ型胶原表达的关系。一、对象与方法1 .对象 :IgA肾病患者 2 4例 ,男 1 4例 ,女 1 0例 ,年龄1 6～ 49岁 ,平均 (2 8 6± 1 1 7)岁。所有患者均行肾活检术 ,肾组织病理检查符合IgA肾病诊断。根据病理改变的程度分…     

结直肠癌患者血清中血管内皮生长因子的水平及其意义

目的:测定结直肠癌患者血清血管内皮生长因子(VEGF)的含量,分析其与临床病理指标间的关系。方法:采用ELISA法测定42例初治结直肠癌患者血清VEGF含量,正常对照30例。结果:结直肠癌患者血清VEGF浓度为274.21±218.38 pg/ml,明显高于正常对照组浓度(169.06±68.01 pg/ml,P<0.02),结肠癌患者血清VEGF浓度为346.52±168.57 pg/ml明显高于直肠癌患者(237.31±124.10 pg/ml,P<0.05)。Dukes B、C、D期组患者血清VEGF浓度与对照组相比均有明显差异(P<0.05),Dukes D期组与Dukes A、B、C期组亦均有明显差异(P<0.05)。结直肠癌患者血清VEGF浓度与年龄、性别无相关性(P>0.05)。结论:VEGF与结直肠癌的发生发展及癌肿部位有关,对探讨结直肠癌的发生机制,病情判断,预后及指导治疗有一定价值,对早期诊断似无帮助。     

Changes of Serum Vascular Endothelial Growth Factor Concentrations in Acute Myoardial Infarction Rats and Patients

Objective To investigate thechanges of serum vascular endothelial growth factor (VEGF) concentration in a rat model of acute myocar-dial infarction (AMI) and in patients with AMI before and after thrombolytic therapy. Methods Eighty-eight male Sprague-Dawley rats were used and sixteen patients with AMI were studied in this study. AMI was produced by left coronary arterial ligation in 80 animals, and eight rats undergoing thoracotomy but not coronary ligation served as sham controls. The blood samples of rats were drawn from the right atrium before (0 hour, sham animals) and 1, 3, 6, 12 or 24 hours and 2, 3, 5, 7or 14 days after AMI (n = 8, respectively) . The blood samples of patients with AMI were collected from an antecubital vein before and 3 hours after thrombolytic therapy. Serum VEGF concentrations were measured by a sensitive and specific enzyme-linked immunosorbent assay (ELISA) . Results The mean serum VEGF concentration in 8 sham animals was 66. 99±17. 83pg/ml. Six hours after A-MI, the level     

高血压患者血肝细胞生长因子与血管内皮功能的关系及干预研究

目的研究高血压患者血清肝细胞生长因子(HGF)与血管内皮功能不全的相关性;氯沙坦/氢氯噻嗪复方片(海捷亚)是否可降低高血压患者血清HGF水平和改善血管内皮功能。方法高血压(HT)患者70例,包括1级高血压(HT1组)患者27例、2级高血压(HT2组)患者31例、3级高血压(HT3组)患者12例。选择其中30例HT患者行海捷亚干预治疗。20例健康体检者为正常对照组。分别测定基线及海捷亚治疗后血清HGF、血浆内皮素(ET)和血清一氧化氮(NO)水平。结果1)血HGF和ET水平:HT3组高于HT2组、HT1组和对照组(P均<0.05),HT2组和HT1组高于对照组(P均<0.05),HT2组和HT1组之间无显著性差异(P值分别为0.061和0.162);血清NO水平:HT各组均低于对照组,且随着血压级别的增高而降低(P均<0.05);2)相关分析结果显示:血清HGF与NO呈负相关、与ET呈正相关(相关系数分别为-0.633、0.741,P值均<0.01);3)海捷亚治疗8周后血清HGF和ET明显降低,而血清NO明显增高(P值均<0.01)。结论1)高血压患者血清HGF增高,其水平可能反映了血管内皮功能不全的严重程度;2)高血压患者应用海捷亚治疗后血清HGF水平下降、血管内皮功能改善。     

子痫时可溶性血管内皮生长因子受体1的变化

目的研究可溶性血管内皮生长因子受体1(sVEGFR-1)和血管内皮生长因子(VEGF)在子痫前期及子痫患者血清中的浓度变化,探讨sVEGFR-1和VEGF在妊娠期高血压(子痫前期及子痫)中的作用。方法采用酶联免疫吸附试验(ELISA)分别测定轻度子痫前期(n=9)、重度子痫前期(n=10)及子痫(n=5)患者(子痫组,总共n=24)与正常妊娠妇女(对照组,n=18)外周血清中sVEGFR-1和VEGF的浓度。结果(1)子痫组各组外周血清中sVEGFR-1水平[子痫前期轻度:(58±7)mg/L、子痫前期重度:(82±15)mg/L、子痫:(96±13)mg/L]明显高于对照组[(11±3)mg/L,P<0·01],子痫前期重度和子痫组高于子痫前期轻度组(P<0·05);(2)子痫组各组外周血血清中VEGF水平[子痫前期轻度:(0·37±0·04)mg/L、子痫前期重度:(0·24±0·04)mg/L、子痫:(0·16±0·01)mg/L]明显低于对照组[(0·43±0·04)mg/L,P<0·05～0·01],子痫前期重度和子痫组低于子痫前期轻度组(P<0·05～0·01);(3)正常妊娠妇女外周血血清中sVEGFR-1水平与妊娠周数成正相关(r=0·508,P<0·05),子痫前期及子痫组血清中sVEGFR-1水平与妊娠周数无关。结论外周血中升高的sVEG-FR-1和降低的VEGF可能与妊娠期高血压(子痫前期及子痫)的发病有关,并参与了子痫前期及子痫的病理生理过程。     

血管内皮生长因子与心肌缺血

血管内皮生长因子（VEGF）是内皮细胞特异性的促有丝分裂原,属分泌性的糖蛋白。有促进内皮细胞增生,增强血管通透性;加速新血管形成的作用。VEGF通过与其特异性受体结合发挥生物学作用。VEGF在生理和病理状态下新生血管形成中起重要作用。VEGF及其受体在缺血和／或缺 氧的 心肌细胞中表达升高。VEGF蛋白应用于心肌缺血可以通过促进缺血区新生血管形成,提高侧枝血流量而改善心功能。VEGF基因治疗心肌缺血具有广阔应用前景。     

Clinical Relevance of Serum Vascular Endothelial Growth Factor and Interleukin-6 in Patients With Colorectal Cancer

Background/Aim:

Some biological factors play a role in stimulation of malignant growth, metastasis and angiogenesis; however, their clinical relevance has not yet been well established for most of them. This work was aimed at studying the clinical relevance of serum vascular endothelial growth factor (VEGF) and interleukin -6 (IL-6), in patients with colorectal cancer (CRC).

Materials and Methods:

Preoperative serum levels of VEGF and IL-6 were measured by enzyme -linked immuno -assay in 35 CRC patients and in 30 healthy controls.

Results:

CRC patients with or without metastasis had significantly higher VEGF and IL-6 levels than healthy controls (all P < 0.001). Patients with advanced clinical stage had significantly higher levels of VEGF and IL-6 than those with early clinical stage (all P < 0.001). Also, patients with metastatic disease had significantly higher VEGF and IL-6 levels than those with localized disease (all P < 0.001). The diagnostic accuracy for invasiveness was 83% for VEGF (cut off value = 240 pg/ml) and 66% for IL-6 (cut off value = 6.7 pg/ml), with sensitivity 79% and 74% and specificity 68% and 59%, respectively.

Conclusion:

In CRC patients, preoperative measurement of serum VEGF and Il-6 may prove useful non-invasive diagnostic indicators associated with advanced clinical stage and tumor metastasis that warrants further investigations.     

血管内皮生长因子与自发性高血压大鼠血管重构的关系

目的探讨血管内皮生长因子与血管重构的关系。方法12只13周龄雄性自发性高血压大鼠(SHR组)作为观察组,12只同周龄雄性WKY大鼠作为正常血压对照组(WKY组)。分别于实验的第4、8周末每组处死大鼠各6只。采用酶联免疫吸附法测定血浆血管内皮生长因子浓度;放射免疫法测定颈动脉血管紧张素Ⅱ浓度;病理图象管理系统测定颈动脉管腔横截面积、内弹力层围绕面积、外弹力层围绕面积,评价内膜和中膜增生程度;免疫组织化学法检测颈动脉血管内皮生长因子蛋白表达。结果与WKY组比较,SHR组血浆血管内皮生长因子浓度明显下降,颈动脉血管内皮生长因子蛋白表达明显减弱,颈动脉血管紧张素Ⅱ浓度却显著升高(P<0.01),8周末这一作用更加显著(P<0.01);SHR组内膜增生较WKY组明显,中膜面积显著增大(P<0.01)。结论在血管重构过程中,血管内皮生长因子水平下降,提示血管内皮生长因子可能具有改善血管重构的作用。     

血管内皮生长因子与动脉粥样硬化

血管内皮生长因子(VEGF)因其潜在的治疗前景引起了国内外的广泛关注。然而,近年来研究发现VEGF可促进动脉粥样硬化的发生和发展。文章就VEGF的分子特征、受体、表达调控、功能及其与动脉粥样硬化的关系作了综述。     

Absence of Clinical Prognostic Value of Vascular Endothelial Growth Factor and Microvessel Density in Multiple Myeloma

Vascular endothelial growth factor (VEGF) is considered a potent stimulator of angiogenesis. In multiple myeloma (MM), it has been reported that bone marrow angiogenesis parallels tumor progression and correlates with a poor prognosis. To investigate the role of angiogenesis in MM, we investigated VEGF expression and microvessel density (MVD) in the bone marrow of 75 MM patients by immunohistochemical methods. VEGF expression was observed in 87.3% (62 of 71) of patients. MVD was 69.42 +/- 9.67 (mean +/- SE) compared with the normal control values of 26.81 +/- 2.85. MVD values were 73.98 +/- 11.27 and 36.04 +/- 6.99 in the VEGF-positive and VEGF-negative groups, respectively. The MVD of patients in the VEGF-positive group was significantly higher than in the VEGF-negative group (P = .045). However, there were no significant differences in various clinical parameters, such as age, sex, hemoglobin, platelet count, serum levels of albumin, calcium, creatinine, and beta2-microglobulin, and bone marrow plasma cell percentage, between the VEGF-positive and VEGF-negative groups. Multivariate analysis revealed that age, hemoglobin, platelet count, serum levels of albumin and creatinine, and bone marrow plasma cell percentage were correlated with overall survival, whereas VEGF expression or MVD was not. In conclusion, our results suggest that VEGF is highly expressed and that MVD is increased in MM, indicating that angiogenesis may play a role in MM. Although MVD in the bone marrow of the VEGF-positive group is significantly higher compared with the VEGF-negative group (P = .045), VEGF is not correlated with overall survival. Further studies that include other angiogenic factors are needed to determine the functional role of angiogenesis in MM.